

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**CanSino Biologics Inc.**  
**康希諾生物股份公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 6185)**

**INSIDE INFORMATION**  
**RESULTS FORECAST FOR THE YEAR 2025**

This announcement is made by CanSino Biologics Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

**I. RESULTS FORECAST**

**(1) Period of the results forecast**

The period of the results forecast is from January 1, 2025 to December 31, 2025 (the “**Reporting Period**”).

**(2) Details of the results forecast**

1. Based on the PRC Generally Accepted Accounting Principles, the Group’s revenue for the year ended December 31, 2025 is expected to be RMB1,040.0 million to RMB1,080.0 million. Compared to the corresponding period of last year, this represents an increase of RMB193.7 million to RMB233.7 million, a year-on-year increase of 22.88% to 27.61%.
2. The net profit attributable to the shareholders of the Company for the year ended December 31, 2025 is expected to be RMB24.5 million to RMB29.0 million. Compared to the corresponding period of last year, this represents a turnaround from loss to profit.

3. The net loss attributable to the shareholders of the Company after deducting the non-recurring profit or loss for the year ended December 31, 2025 is expected to be RMB91.0 million to RMB96.0 million.

**(3) Audit status of the results forecast**

This results forecast has not been audited or reviewed by independent auditors.

**II. PERFORMANCE IN THE CORRESPONDING PERIOD OF LAST YEAR**

During the corresponding period in 2024, based on the PRC Generally Accepted Accounting Principles, the Group achieved revenue of approximately RMB846.3 million, a total loss of approximately RMB381.2 million, a net loss attributable to the shareholders of the Company of approximately RMB378.9 million, and a net loss attributable to the shareholders of the Company after deducting non-recurring profit or loss of approximately RMB441.3 million. The basic earnings per share was RMB-1.53 per share.

**III. REASONS FOR CHANGES IN RESULTS**

**(1) Impact of main business**

During the Reporting Period, the Group adhered to its innovation-centric strategy with a focus on commercialization. As the first MCV4 vaccine product in the Chinese market, Menhycia® has driven sustained growth in revenue. Meanwhile, the Group has further advanced cost reduction and efficiency improvement, with various expenses being effectively controlled. The coordination between production and sales has also been optimized, contributing to an improvement in the gross profit margin. Overall profitability has improved significantly, with the Group successfully achieving a positive net profit attributable to the shareholders of the Company during the Reporting Period.

**(2) Impact of non-recurring profit or loss**

During the Reporting Period, with the advanced progress of the Group's research and development and the efforts of international collaboration, the Group has obtained more government grants and international funding support. As a result, a significant amount of non-recurring profit was generated during the Reporting Period.

#### **IV. RISK WARNING**

There are no major uncertainties related to the Group that may affect the accuracy of the results forecast.

#### **V. OTHER INFORMATION**

The results forecast above is only a preliminary calculation performed by the Group. The specific and accurate financial data shall be subject to the audited annual report of 2025 to be officially disclosed by the Group. Investors are reminded to exercise caution when making investment decisions.

By order of the Board  
**CanSino Biologics Inc.**  
**Xuefeng YU**  
*Chairman*

Hong Kong, January 27, 2026

*As of the date of this announcement, the board of directors of the Company comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO and Ms. Jing WANG as executive Directors, Mr. Chi Shing LI as a non-executive Director, and Mr. Yiu Leung Andy CHEUNG, Mr. Man CHO and Ms. Xuefeng JI as independent non-executive Directors.*